Heparanase is the only mammalian enzyme that cleaves heparan sulphate, an important
component of the extracellular matrix. This leads to the remodelling of the extracellular …

Proteoglycans control numerous normal and pathological processes, among which are
morphogenesis, tissue repair, inflammation, vascularization and cancer metastasis. During …

Malignant conditions are frequently associated with a hypercoaguable state, with recurrent
thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the …

Nanotechnology-based drug delivery systems, including siRNA, present an innovative
approach to treating breast cancer, which disproportionately affects women. These systems …

Today, cancer is one of the main health‐related challenges, and in the meantime, breast
cancer (BC) is one of the most common cancers among women, with an alarming number of …

Recently, nucleic acid drugs have been considered as promising candidates in treatment of
various diseases, especially cancer. Because of developing resistance to conventional …

Breast cancer is the leading cause of cancer-related deaths among women globally. The
difficulties with anticancer medications, such as ineffective targeting, larger doses, toxicity to …

Heparanase (HPA), an endo-hD-glucuronidase that cleaves the heparan sulfate chain of
heparan sulfate proteoglycans, is overexpressed in majority of human cancers. Recent …

Since the approval of bevacizumab as anti-angiogenic therapy in 2004 by the FDA, an array
of angiogenesis inhibitors have been developed and approved. However, results were …

Current guidelines recommend low-molecular-weight heparin treatment in patients with
cancer with established venous thromboembolism (VTE). The aim of this article was to study …